Shortage of influential factors in the evolution of ischemic cardiogenic shock.
DOI:
https://doi.org/10.19230/jonnpr.1306Keywords:
Acute Myocardial Infarction, Age, Survival, RevascularizationAbstract
Objective: To evaluate the influence of age on long-term prognosis of patients with ischemic cardiogenic shock who were treated with early coronary revascularization.
Methods: Prospective observational study of patients that were admitted to the Coronary Care Unit between 1 January 2006 and 1 January 2011 with diagnosis of ischemic cardiogenic shock who were treated by coronary revascularization in the first 72 hours. There was a follow up of the patients during hospitalization and after discharge, completing a follow-up of 5 years.
Results: 97 patients diagnosed with ischemic cardiogenic shock were admitted , of whom 44 were patients aged 75 years or older. Males in group of patients ? 75 years was 56 %, significantly lower vs males in group of patients < 75 years (81 %, p: 0.009). No significant differences were found between both groups with regard to the history of hypertension, dyslipidemia, atherosclerotic disease or associated pathologies (chronic obstructive pulmonary disease, ACV or chronic renal failure). There were a greater number of diabetic patients (20.4 % vs 49 %, p: 0.004) and fewer smokers (4.5 % vs 39.6 %, p: 0.001) in group of patients ? 75 years. No differences were found in type or location of myocardial infarction, being similar incidence of left main coronary artery disease or multivessel disease. Percutaneous coronary revascularization was performed in all patients. No differences were found in TIMI preand post- revascularization or multivessel revascularization (20.4 % of patients ? 75 years vs 15 % of younger patients, p = 0.3). Use of glycoprotein IIb/IIIa inhibitors and intra-aortic balloon pump were similar between two groups. There was no difference in mortality during hospitalization according to the sex of patients, but there was a clear influence in prognosis of LVEF. The patients who died during follow-up, 73.8 % had a LVEF <35 %, p 0.02). Performing an analysis of survival by age groups stratified by LVEF, again it shows that regardless of LVEF, patients aged ? 75 years have lower survival compared to younger patients.
Conclusions: Only age ? 75 years , LVEF <35 % and previous atherosclerotic disease were independent variables associated with mortality during follow-up.
Downloads
References
Thygesen K, Alpert JS, White HD, Group B, Jaffe AS, Apple FS, et al. Universal definition of myocardial infarction: White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007;28(20):2525–38.
Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack C V., Kirk JD, et al. Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE initiative). Am J Cardiol 2006;97(4):437–42.
Rokos IC, French WJ, Koenig WJ, Stratton SJ, Nighswonger B, Strunk B, et al. Integration of pre-hospital electrocardiograms and ST-elevation myocardial infarction receiving center (SRC) networks. Impact on door- toballoon times across 10 independent regions. JACC Cardiovasc Interv. American College of Cardiology Foundation; 2009;2(4):339–46.
Jernberg T, Lindahl B, Wallentin L. The combination of a continuous 12-lead ECG and troponin T. A valuable tool for risk stratification during the first 6 hours in patients with chest pain and a non-diagnostic ECG. Eur Heart J. 2000;21(17):1464–72.
Heeschen C, Goldmann BU, Terres W, Hamm CW. Cardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status. Eur Heart J 2000;21(14):1159–66.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33(20):2551–67.
Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33(18):2252–7.
Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J 2014;35(9):552–6.
Lucas J, Schiller J, Benson V. Summary Health Statistics for U . S . Children : National Health Interview Survey. Vital Heal Stat 2004;218:1– 34.
Ryan D. Acute myocardial infarction. In: Manual of Cardiovascular medicine. 2009. p. 1–27.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015;e29-e322 p.
Petersen S, Peto V, Rayner M. Coronary heart disease statistics. 2004.
Ferreira-González I, Permanyer-Miralda G, Marrugat J, Heras M, Cuñat J, Civeira E, et al. Estudio MASCARA (Manejo del Síndrome Coronario Agudo. Registro Actualizado). Resultados globales. Rev Esp Cardiol 2008;61(8):803–16.
Marrugat J, Elosua R, Martí H. Epidemiología de la cardiopatía isquémica en España: estimación del número de casos y de las tendencias entre 1997 y 2005. Rev Esp Cardiol 2002;55(4):337–46.
Fox K. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23(15):1177–89.
Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002;23(15):1190–01.
Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafrici A, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999;281(8):707–13.
Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil H a W, et al. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group. Heart 1998;80(1):40–4.
Terkelsen CJ, Lassen JF, Nørgaard BL, Gerdes JC, Jensen T, Gøtzsche LBH, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: Observations from an unselected cohort. Eur Heart J 2005;26(1):18–26.
Sociedad D, Cardiología E De, Miembros A, Christian DT, Moderador WH, Bassand J, et al. Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST Grupo de Trabajo para el manejo del infarto agudo de miocardio con elevación del segmento ST. Rev Esp Cardiol 2014;66(1):1–55.
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento de los síndromes coronarios agudos en pacientes. Rev Esp Cardiol 2015;68(12):1125e1–1125e64.
O’Doherty M, Tayler DI, Quinn E, Vincent R, Chamberlain DA. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J 1983;286(6375):1405–8.
Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 2009;301(17):1779–89.
Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane database Syst Rev 2010;(6):CD007160.
Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 2015;131(24):2143–50.
Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilator therapy. N Engl J Med 1987;317(17):1055–9.
Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA 2005;293(23):2865–72.
Ndrepepa G, Kastrati A, Mehilli J, Antoniucci D, Schomig A. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. JAMA 2009;301(5):487–8.
Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341(19):1413–9.
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003;361(9351):13– 20.
De Araújo Gonçalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: Sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005;26(9):865–72.
Calculadora GRACE 2.0 [Internet]. Available from:
http://www.gracescore.org/WebSite/default.aspx?ReturnUrl=%2f
Mehta SR, Granger CB, Boden WE, Steg PG, Bassand J-P, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;360(21):2165–75.
Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early Invasive therapy in acute coronary syndromes. A meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006;48(7):1319–25.
Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Mccullough P a, et al. Early invasive vs conservative treatment unstable angina and non – ST-segment. JAMA 2008;300(1):71–80.
Floyd KC, Yarzebski J, Spencer FA, Lessard D, Dalen JE, Alpert JS, et al. A 30-year perspective (1975-2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: Worcester Heart Attack Study. Circ Cardiovasc Qual Outcomes 2009;2(2):88–95.
Perez-Castellano N, Garcia E, Serrano JA, Elizaga J, Soriano J, Abeytua M, et al. Efficacy of invasive strategy for the management of acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 1999;83(7):989–93.
Hands ME, Rutherford JD, Muller JE, Davies G, Stone PH, Parker C, et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol 1989;14(1):40–8.
Thompson, Ian M, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362(4):779–89.
Hochman J, Sleeper L, Webb J, Sanborn T, White H, Talley J. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341(9):625–34.
Sjauw KD, Engström AE, Vis MM, Van Der Schaaf RJ, Baan J, Koch KT, et al. A systematic review and metaanalysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: Should we change the guidelines? Eur Heart J 2009;30(4):459–68.
Prasad A, Lennon RJ, Rihal CS, Berger PB, Holmes DR. Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J 2004;147(6):1066–70.
Samadi A, Feuvre C Le, Y. A, Collet JP, Barthelemy O, Beygui F, et al. Medium-term survival after primary angioplasty for myocardial infarction complicated by cardiogenic shock after the age of 75 years. Arch Cardiovasc Dis 2008;101(3):175–80.
Lim SY, Jeong MH, Bae EH, Kim W, Kim JH, Hong YJ, et al. Predictive factors of major adverse cardiac events in acute myocardial infarction patients complicated by cardiogenic shock undergoing primary percutaneous coronary intervention. Korean J Intern Med 2005;69(2):154–8.
Hasdai D, Holmes DR, Topol EJ, Berger PB, Criger DA, Hochman JS, et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Eur Heart J 1999;20(2):128–35.
Zimmermann S, Ruthrof S, Nowak K, Klinghammer L, Ludwig J, Daniel WG, et al. Outcomes of contemporary interventional therapy of ST elevation infarction in patients older than 75 years. Clin Cardiol 2009;32(2):87–93.
De Felice F, Fiorilli R, Parma A, Musto C, Nazzaro MS, Confessore P, et al. Comparison of one-year outcome of patients aged <75 years versus 75 years undergoing “rescue” percutaneous coronary intervention. Am J Cardiol 2011;108(8):1075–80.
Tomassini F, Gagnor A, Migliardi A, Tizzani E, Infantino V, Giolitto S, et al. Cardiogenic shock complicating acute myocardial infarction in the elderly: Predictors of long-term survival. Catheter Cardiovasc Interv 2011;78(4):505–11.
Savonitto S, Morici N, De Servi S. El tratamiento de síndromes coronarios agudos de ancianos y pacientes con comorbilidades. Rev Esp Cardiol 2014;67(7):564–73.
The Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2014;35(37):2541–619.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
